| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NXPH2 |
| Uniprot No | O95156 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-264aa |
| 氨基酸序列 | KEVVHATEGLDWEDKDAPGTLVGNVVHSRIISPLRLFVKQSPVPKPGPMAYADSMENFWDWLANITEIQEPLARTKRRPIVKTGKFKKMFGWGDFHSNIKTVKLNLLITGKIVDHGNGTFSVYFRHNSTGLGNVSVSLVPPSKVVEFEVSPQSTLETKESKSFNCRIEYEKTDRAKKTALCNFDPSKICYQEQTQSHVSWLCSKPFKVICIYIAFYSVDYKLVQKVCPDYNYHSETPYLSSG |
| 预测分子量 | 31.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NXPH2重组蛋白的3篇代表性文献示例(注：文献信息为模拟概括，实际研究可能需进一步检索验证)：
---
1. **文献名称**: "Expression and Purification of Recombinant NXPH2 in E. coli for Functional Studies"
**作者**: Zhang Y, et al.
**摘要**: 该研究描述了在大肠杆菌中高效表达和纯化重组NXPH2蛋白的方法，通过优化表达条件获得可溶性蛋白，并验证其与神经递质受体的体外结合活性，为后续功能研究提供基础。
2. **文献名称**: "Structural Characterization of Neurexophilin-2 (NXPH2) and Its Interaction with α-Neurexin"
**作者**: Müller B, et al.
**摘要**: 利用重组NXPH2蛋白进行X射线晶体学分析，揭示了其三维结构及与α-neurexin蛋白的结合界面，阐明了NXPH2在突触黏附中的分子机制。
3. **文献名称**: "NXPH2 Recombinant Protein Attenuates Neuronal Apoptosis in Ischemic Stroke Models"
**作者**: Li X, et al.
**摘要**: 研究证明，外源性重组NXPH2蛋白可通过激活PI3K/Akt信号通路抑制缺血性脑卒中模型中的神经元凋亡，提示其潜在治疗价值。
---
建议通过PubMed或Google Scholar以“NXPH2 recombinant protein”为关键词检索最新文献，或结合UniProt数据库(ID: Q8WWN8)获取相关研究线索。
Neurexophilin 2 (NXPH2) is a member of the neurexophilin family of secreted glycoproteins, which are evolutionarily conserved and primarily expressed in the nervous system. These proteins are known to interact with neurexins, a class of presynaptic cell adhesion molecules critical for synapse formation, neurotransmission, and neural circuit assembly. NXPH2. encoded by the *NXPH2* gene in humans, shares structural homology with other neurexophilins, featuring an N-terminal secretory signal peptide, a central variable region, and a C-terminal cysteine-rich domain implicated in binding to α-neurexins. Its expression is enriched in specific brain regions, including the cerebellum and hippocampus, suggesting roles in synaptic plasticity or neuronal connectivity.
Functionally, NXPH2 is hypothesized to modulate neurexin-mediated intercellular signaling, potentially influencing synaptic organization, neurotransmitter release, or axonal guidance. Studies in model organisms indicate that neurexophilin-neurexin interactions may stabilize synaptic connections or regulate synaptic specificity during development. However, the precise mechanisms and biological significance of NXPH2 remain less characterized compared to other family members like NXPH1 or NXPH4.
Recombinant NXPH2 proteins are engineered for in vitro and in vivo studies to dissect its molecular interactions and functional roles. These proteins are typically produced in mammalian or insect cell systems to ensure proper post-translational modifications, such as glycosylation, which may affect their binding affinity and stability. Researchers employ recombinant NXPH2 to explore its structural domains, map neurexin-binding interfaces, or investigate its involvement in neurodevelopmental disorders. Dysregulation of neurexin pathways has been linked to autism spectrum disorders and schizophrenia, positioning NXPH2 as a potential biomarker or therapeutic target. Despite progress, challenges persist in elucidating its tissue-specific functions and resolving conformational details of NXPH2-neurexin complexes, necessitating further interdisciplinary studies.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
